Tris and the ready production of drug-fatty acyl conjugates

Drug Development Research

Volumn 46, Issue 3-4, 1999, Pages 302-308

  Wells, Xanthe E ^a   Bender, Vera J ^a   Francis, Craig L ^a   He Williams, Hua Ming ^a   Manthey, Michael K ^a   Moghaddam, Minoo J ^a   Reilly, Wayne G ^a   Whittaker, Robert G ^a  

^a CSIRO   (Australia)

Author keywords

Drug delivery; Profiles; Retention; Toxicity

Indexed keywords

CHLORAMBUCIL; DRUG; FATTY ACID; INDOMETACIN; METHOTREXATE; MORPHINE; TROMETAMOL; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; LIPOPHILICITY; MOUSE; NONHUMAN;

EID: 0033037470     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199903/04)46:3/4<302::AID-DDR16>3.0.CO;2-R     Document Type: Article

References (27)

1. Anel A, Halmos T, Torres JM, Pineiro A, Antonakis K, Uriel J. 1990. Cytotoxicity of chlorambucil and chlorambucil-fatty acid conjugates against human lymphomas and normal human peripheral blood lymphocytes. Biochem Pharmacol 40:1193-1200.
2. Cameron FH, Moghaddam MJ, Bender VJ, Whittaker RG, Lockett TJ. 1999. A transfection compound series based on a versatile tris linkage. Biochim Biophys Acta 1417:37-50.
3. Garzon-Aburbeh A, Poupaert JH, Claesen M, Dumont P, Atassi G. 1983. 1,3-dipalmitoylglycerol ester of chlorambucil as a lymphotrophic, orally administrable antineoplastic agent. J Med Chem 26:1200-1203.
4. Garzon-Arburbeh A, Poupaert JH, Claesen M, Dumont P 1986. A lymphotrophic prodrug of L-dopa: synthesis, pharmacological properties, and pharmacokinetic behaviour of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl]propane-1,2, 3-triol. J Med Chem 29:687-691.
5. Gozes I, Fridkin M. 1992. A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model. J Clin Invest 90:810-814.
6. Jacobson KA, Zimmet J, Schulick R, Barone S, Daly JW, Kirk KL. 1987. Adenosine analogs with covalently attached lipids have enhanced potency at Al-adenosine receptors. FEBS Lett 225:97-102.
7. Hashimoto K, Loader JE, Kinsky SC. 1985. Synthesis and characterisation of methotrexate-dimyristolphosphatidylethanolamine derivatives and the glycerphosphorylethanolamine analogs. Biochim Biophys Acta 816:163-168.
8. Hashizume M, Douen T, Murakami M, Yamamoto A, Takada K, Muranishi S. 1992. Improvement of large intestinal absorption of insulin by chemical modification with palmitic acid in rats. J Pharm Pharmacol 44:555-559.
9. Jona JA, Dittert LW, Crooks PA, Milosovich SM, Hussain AA. 1995. Design of novel prodrugs for the enhancement of the transdermal penetration of indomethacin. Int J Pharm 123:127-136.
10. Patel D, McKinely BD, Davis TP, Porreca F, Yamamura HI, Hruby VJ. 1997. Peptide targeting and delivery across the blood-brain barrier utilizing synthetic triglyceride esters: design, synthesis, and bioactivity. Bioconjug Chem 8:434-441.
11. Porter CJ. 1997. Drug delivery to the lymphatic system. Crit Rev Ther Drug Carrier Syst 14:333-393.
12. Reilly WG, Whittaker RG, Jennings PA, Finney KG. 1991. Self adjuvanting peptide vaccine delivery system and production thereof. Patent PCT/AU92/00377. Filed 26/7/91.
13. Rosowsky A, Forsch RA, Yu CS, Lazarus H, Beardsley GP 1984. Methotrexate analogues. 21. Divergent influence of alkyl chain length on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monoesters. J Med Chem 27:605-609.
14. Schwender RA, Schott H. 1996. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. J Cancer Res Clin Oncol 122:723-726.
15. Scriba GK, Lambert DM, Poupaert JH. 1995. Bioavailability of phenytoin following oral administration of phenytoin-lipid conjugates to rats. J Pharm Pharmacol 47:945-948.
16. Setoh K, Murakami M, Araki N, Fujita T, Yamamoto A. 1995. Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids. J Pharm Pharmacol 47:808-811.
17. Steim JM, Camaioni NC, Sarin PS, Sun DK, Sehgal RK, Turcotte JG. 1990. Lipid conjugates of antiretroviral agents. I. Azidothymidine-monophosphate-diglyceride: anti-HIV activity, physical properties, and interaction with plasma proteins. Biochem Biophys Res Commun 171:451-457.
18. Toth I. 1994. A novel chemical approach to drug delivery: lipid amino acid conjugates. J Drug Target 2:217-239.
19. van Wijk GM, Hostetler KY, Kroneman E, Richman DD, Sridhar CN, Kumar R, van den Bosch H. 1994. Synthesis and antiviral activity of 3'-azido-3'-deoxythymidine triphosphate distearoylglycerol: a novel phospholipid conjugate of the anti-HIV agent AZT. Chem Phys Lipids 70:213-222.
20. Verhoef JC, Bodde HE, de Boer AG, Bouwstra JA, Junginger HE, Merkus FW, Breimer DD. 1990. Transport of peptide and protein drugs across biological membranes. Eur J Drug Metab Pharmacokinet 15:83-93.
21. Wall ME, Abernethy GS, Carroll FI, Taylor DJ. 1969. The effects of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems. J Med Chem 12:810
22. Welch CJ, Larsson A, Ericson AC, Oberg B, Datema R, Chattopadhyaya J. 1985. The chemical synthesis and anti-viral properties of an acyclovir-phospholipid conjugate. Acta Chem Scand 39:47-54.
23. Whittaker RG, Hayes PJ, Bender VJ. 1993a. A gentle method for linking tris to amino acids and peptides. Pept Res 6:125-128.
24. Whittaker RG, Bender VJ, Reilly WG. 1993b. Therapeutic conjugates. Patent PCT/AU94/00440. Filed 2/8/93.
25. Whittaker RG, Bender VJ, Reilly WG, Moghaddam MJ. 1995. Improved therapeutic agents. Patent PCT/AU96/0015. Filed 16/1/95.
26. Williams AS, Love WG, Williams BD. 1992. Synthesis of methotrexate-dimyristoylphosphatidylethanolamine analogs and characterization of methotrexate release in vitro. Int J Pharm 85:189-197.
27. Williams AS, Topley N, Amos N, Williams BD. 1994. Effect of three lipophilic methotrexate derivatives upon mediator release by lipopolysaccharide-stimulated rat peritoneal macrophages. J Pharm Pharmacol 46:291-295.